Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study
Open Access
- 7 May 2020
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (3), 859-862
- https://doi.org/10.3324/haematol.2019.224535
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Novel therapies for relapsed/refractory mantle cell lymphomaBest Practice & Research Clinical Haematology, 2018
- Unification of de novo and acquired ibrutinib resistance in mantle cell lymphomaNature Communications, 2017
- Abstract 2830: The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6Cancer Research, 2016
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481SBTKMutation Revealed by Longitudinal Functional Genomics in Mantle Cell LymphomaCancer Discovery, 2014
- Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor XenograftsClinical Cancer Research, 2014
- Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) StudyJournal of Clinical Oncology, 2013
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaThe New England Journal of Medicine, 2013
- Abstract LB-122: LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer.Cancer Research, 2013
- Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell LymphomaJournal of Clinical Oncology, 2006
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's LymphomasJournal of Clinical Oncology, 1999